ReviewEndocrinology and metabolism (Seoul, Korea)2019
Genomic Characterization of Differentiated Thyroid Carcinoma.
Review in Endocrinology and metabolism (Seoul, Korea), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 56 citations in OpenAlex.
- Utilities of next-generation sequencing in the surgical management of thyroid nodules in China.BMC endocrine disorders · 2026Article
- Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.Frontiers in oncology · 2026Article
- Homologous Recombination in Thyroid Tumor Samples.International journal of molecular sciences · 2025Article
- Evaluation of common genetic risk factors for differentiated thyroid cancer in the Thai population.Biomedical reports · 2025Article
- HighCancers · 2025Article
- Detection of PTEN Mutations in Fine Needle Aspiration Biopsies of Indeterminate Thyroid Nodules: Impact on Diagnosis and Prognosis.Head & neck · 2025Article
- Molecular alteration patterns predict tumor behavior in papillary thyroid carcinoma independent of tumor size: insights from an international multicenter retrospective study.Thyroid research · 2025Article
- Comprehensive analysis of the papillary thyroid carcinoma identifies CSGALNACT1 as a proliferation driver and prognostic biomarker.Frontiers in cell and developmental biology · 2025Article
- Small Multi-Gene DNA Panel Can Aid in Reducing the Surgical Resection Rate and Predicting the Malignancy Risk of Thyroid Nodules.Endocrinology and metabolism (Seoul, Korea) · 2024Article
- TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases.Thyroid research · 2024Article
- Radiation-Related Thyroid Cancer.Endocrine reviews · 2024Review
- TLE4 downregulation identified by WGCNA and machine learning algorithm promotes papillary thyroid carcinoma progression via activating JAK/STAT pathway.Journal of Cancer · 2024Article
- Anaplastic thyroid cancer: Pathogenesis, prognostic factors and genetic landscape (Review).Molecular and clinical oncology · 2023Review
- Comparative Analysis of Driver Mutations and Transcriptomes in Papillary Thyroid Cancer by Region of Residence in South Korea.Endocrinology and metabolism (Seoul, Korea) · 2023Article
- Advances in transcriptomics and proteomics in differentiated thyroid cancer: An updated perspective (Review).Oncology letters · 2023Review
- FDG uptake reflects an immune-enriched subtype of thyroid cancer: Clinical implications of imaging-based molecular characterization.Cancer medicine · 2023Article
- Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2023Article
- The role of EZH1 and EZH2 in development and cancer.BMB reports · 2022Review
- Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers.Endocrine-related cancer · 2022Review
- Tackling Thyroid Cancer in Europe-The Challenges and Opportunities.Healthcare (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Since the release of The Cancer Genome Atlas study of papillary thyroid carcinoma (PTC) in 2014, additional genomic studies of differentiated thyroid carcinoma (DTC) using massively-parallel sequencing (MPS) have been published. Recent advances in MPS technology have started to provide important insights into the molecular pathogenesis of DTC. In the genomic landscape, the most recurrently altered genes in DTC, which has a low mutational burden relative to other cancers, are
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.